CUAMC
BBIO icon

China Universal Asset Management Company’s BridgeBio Pharma BBIO Stock Holding History

China Universal Asset Management Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
31,171
-3,232
-9% -$226K 0.14% 112
2026
Q1 		$2.55M Buy
34,403
+3,001
+10% +$218K 0.19% 89
2025
Q4 		$2.4M Sell
31,402
-2,107
-6% -$138K 0.18% 92
2025
Q3 		$1.74M Sell
33,509
-4,628
-12% -$226K 0.14% 127
2025
Q2 		$1.65M Sell
38,137
-12
-0% -$436 0.16% 125
2025
Q1 		$1.32M Sell
38,149
-1,924
-5% -$64.9K 0.12% 150
2024
Q4 		$1.1M Buy
40,073
+3,908
+11% +$101K 0.1% 149
2024
Q3 		$921K Buy
36,165
+14,181
+65% +$372K 0.1% 144
2024
Q2 		$557K Sell
21,984
-11,790
-35% -$322K 0.08% 135
2024
Q1 		$1.04M Buy
33,774
+13,654
+68% +$464K 0.13% 125
2023
Q4 		$812K Buy
20,120
+15,949
+382% +$479K 0.16% 123
2023
Q3 		$110K Buy
4,171
+2,067
+98% +$58.7K 0.03% 191
2023
Q2 		$36.2K Buy
2,104
+54
+3% +$813 0.01% 225
2023
Q1 		$34K Buy
2,050
+531
+35% +$6.19K 0.01% 179
2022
Q4 		$11.6K Buy
1,519
+131
+9% +$1.25K ﹤0.01% 215
2022
Q3 		$14K Buy
+1,388
New +$14.4K 0.01% 175

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

China Universal Asset Management Company's BBIO Position: Q2 2026 in Review

China Universal Asset Management Company reduced its BridgeBio Pharma (BBIO) stake by 9.4% in Q2 2026, selling an estimated $226K and leaving 31,171 shares worth $2.32M. The position accounts for 0.14% of the portfolio, ranked #112.

China Universal Asset Management Company first reported a position in BBIO in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.55M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • China Universal Asset Management Company held 31,171 shares of BridgeBio Pharma worth $2.32M as of Q2 2026.
  • China Universal Asset Management Company sold 3,232 BridgeBio Pharma shares in Q2 2026, an estimated $226K.
  • BridgeBio Pharma made up 0.14% of China Universal Asset Management Company's portfolio in Q2 2026, its #112 holding.
  • China Universal Asset Management Company first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's BridgeBio Pharma position peaked at $2.55M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.